Refractory systemic capillary leak syndrome treated with bevacizumab: a case report
This article was about a 58-year-old female suffering from refractory systemic capillary leak syndrome after bone marrow transplantation and being treated with bevacizumab, a VEGF inhibitor. In comparison with other successfully treated cases, this patient received four cycles of bevacizumab treatment without symptomatic improvement and eventually died in the intensive care unit. Further studies are needed to further confirm the role of bevacizumab in the management of SCLS.
Source: Angiogenesis - Category: Molecular Biology Source Type: research
More News: Avastin | Bone Marrow Transplant | Intensive Care | Molecular Biology | Study | Transplants